 Cynthia Firnhaber
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Dysplasia | 16 | 2024 | 40 | 5.870 |
Why?
| | Uterine Cervical Neoplasms | 21 | 2024 | 230 | 5.610 |
Why?
| | HIV Infections | 48 | 2025 | 2730 | 4.500 |
Why?
| | Papillomavirus Infections | 18 | 2024 | 297 | 4.050 |
Why?
| | South Africa | 40 | 2021 | 192 | 3.110 |
Why?
| | Papillomaviridae | 11 | 2022 | 114 | 2.530 |
Why?
| | Papanicolaou Test | 7 | 2024 | 42 | 1.830 |
Why?
| | HIV Seropositivity | 8 | 2017 | 119 | 1.640 |
Why?
| | Early Detection of Cancer | 8 | 2024 | 370 | 1.600 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 39 | 1.520 |
Why?
| | Papillomavirus Vaccines | 5 | 2021 | 232 | 1.480 |
Why?
| | Tuberculosis, Multidrug-Resistant | 9 | 2019 | 57 | 1.390 |
Why?
| | Colposcopy | 4 | 2024 | 15 | 1.280 |
Why?
| | Acquired Immunodeficiency Syndrome | 4 | 2022 | 228 | 1.190 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2020 | 267 | 1.160 |
Why?
| | Cryotherapy | 2 | 2017 | 16 | 1.120 |
Why?
| | Breast Neoplasms | 5 | 2024 | 2133 | 1.100 |
Why?
| | Quality Assurance, Health Care | 5 | 2017 | 317 | 1.090 |
Why?
| | Rifampin | 9 | 2021 | 83 | 1.080 |
Why?
| | Vaginal Smears | 5 | 2024 | 55 | 1.070 |
Why?
| | Optical Imaging | 2 | 2015 | 56 | 0.910 |
Why?
| | Antitubercular Agents | 7 | 2021 | 200 | 0.910 |
Why?
| | HIV-1 | 12 | 2020 | 838 | 0.900 |
Why?
| | Anti-HIV Agents | 12 | 2020 | 757 | 0.830 |
Why?
| | Mammography | 1 | 2024 | 146 | 0.800 |
Why?
| | Adult | 50 | 2025 | 35599 | 0.780 |
Why?
| | Delayed Diagnosis | 2 | 2019 | 79 | 0.750 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2017 | 98 | 0.700 |
Why?
| | Antibiotics, Antitubercular | 3 | 2019 | 37 | 0.700 |
Why?
| | Female | 61 | 2025 | 68734 | 0.690 |
Why?
| | Cost-Benefit Analysis | 5 | 2018 | 569 | 0.620 |
Why?
| | CD4 Lymphocyte Count | 11 | 2018 | 267 | 0.600 |
Why?
| | Access to Information | 1 | 2018 | 47 | 0.580 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2018 | 80 | 0.580 |
Why?
| | Hepatitis B | 2 | 2008 | 66 | 0.570 |
Why?
| | Breast | 1 | 2018 | 153 | 0.570 |
Why?
| | Contraceptive Agents, Female | 2 | 2020 | 78 | 0.560 |
Why?
| | Antibodies, Viral | 4 | 2018 | 602 | 0.550 |
Why?
| | Coinfection | 6 | 2024 | 131 | 0.550 |
Why?
| | Oncology Service, Hospital | 1 | 2017 | 16 | 0.540 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 761 | 0.540 |
Why?
| | Prevalence | 13 | 2018 | 2564 | 0.530 |
Why?
| | Electrosurgery | 1 | 2017 | 44 | 0.530 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 226 | 0.530 |
Why?
| | Humans | 68 | 2025 | 129626 | 0.520 |
Why?
| | Anus Neoplasms | 2 | 2015 | 30 | 0.510 |
Why?
| | Mass Screening | 7 | 2025 | 1190 | 0.500 |
Why?
| | Health Resources | 1 | 2017 | 113 | 0.500 |
Why?
| | Middle Aged | 28 | 2025 | 31136 | 0.490 |
Why?
| | Trichomonas vaginalis | 2 | 2012 | 13 | 0.490 |
Why?
| | Tuberculosis | 5 | 2021 | 273 | 0.490 |
Why?
| | Surgical Instruments | 1 | 2015 | 51 | 0.480 |
Why?
| | Women's Health Services | 1 | 2015 | 16 | 0.470 |
Why?
| | Mobile Health Units | 1 | 2015 | 20 | 0.470 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2015 | 83 | 0.470 |
Why?
| | Viral Load | 8 | 2020 | 449 | 0.460 |
Why?
| | Specimen Handling | 1 | 2015 | 162 | 0.450 |
Why?
| | Health Services Accessibility | 2 | 2019 | 903 | 0.440 |
Why?
| | Precancerous Conditions | 4 | 2020 | 160 | 0.440 |
Why?
| | Rural Health Services | 1 | 2015 | 111 | 0.440 |
Why?
| | Urban Population | 3 | 2018 | 443 | 0.420 |
Why?
| | Genital Neoplasms, Male | 1 | 2012 | 5 | 0.400 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 231 | 0.400 |
Why?
| | Mycoplasma genitalium | 1 | 2012 | 2 | 0.400 |
Why?
| | Urethritis | 1 | 2012 | 3 | 0.400 |
Why?
| | Uterine Cervicitis | 1 | 2012 | 7 | 0.400 |
Why?
| | Neisseria gonorrhoeae | 1 | 2012 | 24 | 0.390 |
Why?
| | HIV | 3 | 2022 | 227 | 0.390 |
Why?
| | Chlamydia trachomatis | 1 | 2012 | 46 | 0.390 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 48 | 0.390 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2008 | 21 | 0.380 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 368 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 627 | 0.370 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1843 | 0.370 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2012 | 123 | 0.370 |
Why?
| | Genital Neoplasms, Female | 1 | 2012 | 82 | 0.360 |
Why?
| | Cervix Uteri | 3 | 2024 | 49 | 0.360 |
Why?
| | Condylomata Acuminata | 1 | 2011 | 7 | 0.360 |
Why?
| | Penile Diseases | 1 | 2011 | 5 | 0.360 |
Why?
| | Protease Inhibitors | 1 | 2011 | 107 | 0.350 |
Why?
| | Neutropenia | 1 | 2010 | 137 | 0.330 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1280 | 0.330 |
Why?
| | Anemia | 1 | 2010 | 161 | 0.310 |
Why?
| | Sexually Transmitted Diseases | 2 | 2025 | 150 | 0.310 |
Why?
| | Thrombocytopenia | 1 | 2010 | 186 | 0.300 |
Why?
| | Diarylquinolines | 2 | 2018 | 12 | 0.300 |
Why?
| | Health Care Costs | 4 | 2018 | 367 | 0.300 |
Why?
| | Delivery of Health Care | 1 | 2015 | 898 | 0.280 |
Why?
| | Anal Canal | 2 | 2018 | 88 | 0.280 |
Why?
| | Women's Health | 1 | 2009 | 364 | 0.270 |
Why?
| | DNA, Viral | 3 | 2018 | 347 | 0.260 |
Why?
| | Young Adult | 15 | 2018 | 12455 | 0.260 |
Why?
| | Disease Progression | 4 | 2016 | 2627 | 0.260 |
Why?
| | Human Papillomavirus DNA Tests | 2 | 2017 | 3 | 0.250 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2046 | 0.250 |
Why?
| | Acetic Acid | 2 | 2016 | 16 | 0.240 |
Why?
| | Atazanavir Sulfate | 2 | 2016 | 41 | 0.240 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1282 | 0.230 |
Why?
| | Treatment Outcome | 10 | 2024 | 10219 | 0.230 |
Why?
| | Prospective Studies | 7 | 2019 | 7135 | 0.230 |
Why?
| | Health Status | 1 | 2009 | 756 | 0.230 |
Why?
| | Tenofovir | 2 | 2017 | 232 | 0.230 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2021 | 35 | 0.230 |
Why?
| | Adolescent | 13 | 2022 | 20412 | 0.230 |
Why?
| | Developing Countries | 4 | 2018 | 284 | 0.220 |
Why?
| | Drug Resistance, Bacterial | 2 | 2016 | 175 | 0.220 |
Why?
| | Laboratories | 2 | 2015 | 108 | 0.220 |
Why?
| | Male | 23 | 2025 | 63670 | 0.210 |
Why?
| | Lamivudine | 2 | 2015 | 61 | 0.210 |
Why?
| | Zidovudine | 2 | 2015 | 78 | 0.210 |
Why?
| | Comorbidity | 3 | 2016 | 1547 | 0.200 |
Why?
| | Vaccination | 3 | 2021 | 1347 | 0.190 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2021 | 5 | 0.190 |
Why?
| | Retrospective Studies | 8 | 2021 | 14522 | 0.180 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2021 | 18 | 0.180 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2018 | 15 | 0.180 |
Why?
| | Aged | 8 | 2019 | 22061 | 0.180 |
Why?
| | United States | 8 | 2025 | 13871 | 0.180 |
Why?
| | Human papillomavirus 18 | 2 | 2011 | 15 | 0.180 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2021 | 88 | 0.170 |
Why?
| | Outpatients | 1 | 2024 | 373 | 0.170 |
Why?
| | Risk Factors | 7 | 2017 | 9786 | 0.170 |
Why?
| | Human papillomavirus 16 | 2 | 2011 | 34 | 0.170 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 253 | 0.170 |
Why?
| | Glycomics | 1 | 2020 | 7 | 0.170 |
Why?
| | Incidence | 4 | 2017 | 2641 | 0.170 |
Why?
| | Mycobacterium tuberculosis | 3 | 2019 | 309 | 0.170 |
Why?
| | Benzoxazines | 2 | 2021 | 30 | 0.170 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2019 | 32 | 0.170 |
Why?
| | Cyclopropanes | 2 | 2021 | 89 | 0.160 |
Why?
| | Alkynes | 2 | 2021 | 56 | 0.160 |
Why?
| | Lopinavir | 3 | 2021 | 30 | 0.160 |
Why?
| | Africa | 3 | 2020 | 99 | 0.160 |
Why?
| | Africa, Southern | 2 | 2016 | 8 | 0.160 |
Why?
| | Ritonavir | 3 | 2021 | 73 | 0.160 |
Why?
| | Urban Health Services | 1 | 2019 | 61 | 0.150 |
Why?
| | Drug Combinations | 2 | 2021 | 331 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 958 | 0.150 |
Why?
| | Brazil | 3 | 2016 | 154 | 0.150 |
Why?
| | South America | 3 | 2016 | 58 | 0.150 |
Why?
| | Anus Diseases | 1 | 2017 | 7 | 0.140 |
Why?
| | Uterus | 1 | 2018 | 207 | 0.140 |
Why?
| | Income | 1 | 2018 | 188 | 0.140 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 28 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2019 | 557 | 0.130 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2012 | 1058 | 0.130 |
Why?
| | Cost of Illness | 1 | 2018 | 277 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 92 | 0.130 |
Why?
| | Atypical Squamous Cells of the Cervix | 1 | 2016 | 1 | 0.130 |
Why?
| | Cross-Sectional Studies | 5 | 2019 | 5075 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2017 | 282 | 0.130 |
Why?
| | Cytisus | 1 | 2015 | 1 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 148 | 0.130 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 23 | 0.120 |
Why?
| | Menopause | 1 | 2018 | 297 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2720 | 0.120 |
Why?
| | Sex Factors | 3 | 2018 | 1970 | 0.120 |
Why?
| | Staining and Labeling | 1 | 2016 | 142 | 0.120 |
Why?
| | Sputum | 2 | 2016 | 302 | 0.120 |
Why?
| | Asia | 2 | 2016 | 58 | 0.120 |
Why?
| | Stavudine | 2 | 2012 | 8 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2018 | 546 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 135 | 0.120 |
Why?
| | Antibodies, Neutralizing | 2 | 2018 | 267 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1213 | 0.110 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 1005 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 172 | 0.110 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 205 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 201 | 0.110 |
Why?
| | Contraception | 1 | 2016 | 153 | 0.110 |
Why?
| | Emtricitabine | 1 | 2015 | 168 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1465 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2016 | 263 | 0.110 |
Why?
| | Markov Chains | 3 | 2018 | 117 | 0.110 |
Why?
| | Bacteriological Techniques | 1 | 2014 | 69 | 0.110 |
Why?
| | RNA, Viral | 2 | 2020 | 620 | 0.100 |
Why?
| | Time Factors | 4 | 2018 | 6555 | 0.100 |
Why?
| | Trichomonas Vaginitis | 1 | 2012 | 4 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2012 | 13 | 0.100 |
Why?
| | Metronidazole | 1 | 2012 | 20 | 0.100 |
Why?
| | Mycobacterium | 1 | 2014 | 106 | 0.100 |
Why?
| | Age Factors | 3 | 2018 | 3152 | 0.100 |
Why?
| | Virus Shedding | 1 | 2012 | 48 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4894 | 0.100 |
Why?
| | Demography | 1 | 2013 | 279 | 0.100 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 3 | 0.090 |
Why?
| | Human papillomavirus 11 | 1 | 2011 | 2 | 0.090 |
Why?
| | Botswana | 1 | 2011 | 8 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 712 | 0.090 |
Why?
| | Internationality | 1 | 2012 | 149 | 0.090 |
Why?
| | Antigens, Viral | 1 | 2012 | 179 | 0.090 |
Why?
| | Vaginosis, Bacterial | 1 | 2011 | 12 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2012 | 118 | 0.090 |
Why?
| | Molecular Typing | 1 | 2011 | 20 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2017 | 715 | 0.090 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 157 | 0.090 |
Why?
| | Lipid Metabolism | 2 | 2011 | 503 | 0.090 |
Why?
| | Caribbean Region | 1 | 2010 | 25 | 0.090 |
Why?
| | Americas | 1 | 2010 | 24 | 0.090 |
Why?
| | Sexual Partners | 1 | 2012 | 185 | 0.090 |
Why?
| | Vagina | 1 | 2012 | 174 | 0.090 |
Why?
| | Cohort Studies | 5 | 2025 | 5426 | 0.080 |
Why?
| | Prognosis | 3 | 2020 | 3774 | 0.080 |
Why?
| | Delayed-Action Preparations | 2 | 2021 | 172 | 0.080 |
Why?
| | Reflex Sympathetic Dystrophy | 1 | 2009 | 4 | 0.080 |
Why?
| | Health Personnel | 1 | 2016 | 653 | 0.080 |
Why?
| | Pregnancy | 3 | 2020 | 6417 | 0.080 |
Why?
| | Autoantigens | 1 | 2012 | 420 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1035 | 0.080 |
Why?
| | Leptin | 1 | 2010 | 220 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 353 | 0.080 |
Why?
| | Cognition | 1 | 2016 | 1129 | 0.070 |
Why?
| | Biopsy | 2 | 2024 | 1088 | 0.070 |
Why?
| | Drug Costs | 2 | 2018 | 100 | 0.070 |
Why?
| | Adiposity | 1 | 2011 | 504 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5415 | 0.060 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 767 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3080 | 0.060 |
Why?
| | Algorithms | 1 | 2012 | 1616 | 0.060 |
Why?
| | Syphilis | 1 | 2025 | 32 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1686 | 0.060 |
Why?
| | Gonorrhea | 1 | 2025 | 57 | 0.060 |
Why?
| | Chlamydia Infections | 1 | 2025 | 72 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1198 | 0.050 |
Why?
| | Contraceptive Effectiveness | 1 | 2021 | 1 | 0.050 |
Why?
| | Nelfinavir | 1 | 2021 | 9 | 0.050 |
Why?
| | Isoniazid | 1 | 2021 | 63 | 0.040 |
Why?
| | Liver | 1 | 2008 | 1842 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1365 | 0.040 |
Why?
| | Reference Standards | 1 | 2020 | 176 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 395 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 170 | 0.040 |
Why?
| | Risk Assessment | 1 | 2008 | 3262 | 0.040 |
Why?
| | Ethiopia | 1 | 2018 | 37 | 0.040 |
Why?
| | Atrophy | 1 | 2018 | 169 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2018 | 106 | 0.040 |
Why?
| | Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 4 | 0.040 |
Why?
| | Proctoscopy | 1 | 2017 | 5 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 328 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 348 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2017 | 32 | 0.030 |
Why?
| | Virus Replication | 1 | 2020 | 452 | 0.030 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.030 |
Why?
| | Child | 2 | 2016 | 20884 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 110 | 0.030 |
Why?
| | Employment | 1 | 2018 | 167 | 0.030 |
Why?
| | Pandemics | 1 | 2025 | 1491 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 175 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2018 | 349 | 0.030 |
Why?
| | Peru | 1 | 2016 | 53 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 68 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 199 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 67 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2016 | 201 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2016 | 321 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 794 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 72 | 0.030 |
Why?
| | Pathology | 1 | 2013 | 22 | 0.030 |
Why?
| | Educational Status | 1 | 2016 | 471 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2013 | 122 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 637 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 42 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1687 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 558 | 0.020 |
Why?
| | Withholding Treatment | 1 | 2012 | 71 | 0.020 |
Why?
| | Serum | 1 | 2011 | 58 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2016 | 346 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2010 | 49 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2011 | 248 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1042 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3968 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 234 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1109 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1159 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2009 | 294 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 482 | 0.020 |
Why?
| | Glucose | 1 | 2010 | 1002 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 3717 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3394 | 0.010 |
Why?
|
|
Firnhaber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|